{{Infobox drug
| IUPAC_name = (2''E'')-''N''-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
| image = Belinostat.svg
| alt = 
| caption =

<!-- Clinical data -->
| tradename = Beleodaq
| Drugs.com = {{Drugs.com|parent|beleodaq}}
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = D
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = [[Intravenous]] (IV)

<!-- Pharmacokinetic data -->
| bioavailability = 100% (IV)
| protein_bound = 92.9–95.8%<ref>{{cite web|title=Beleodaq (belinostat) For Injection, For Intravenous Administration. Full Prescribing Information|url=http://www.beleodaq.com/downloads/Final_Beleodaq_PI.pdf|publisher=Spectrum Pharmaceuticals, Inc. Irvine, CA 92618|accessdate=21 November 2015}}</ref>
| metabolism = [[UDP glucuronosyltransferase 1 family, polypeptide A1|UGT1A1]]
| onset = 
| elimination_half-life = 
| excretion = Urine

<!-- Identifiers -->
| CAS_number = 866323-14-0
| CAS_number_Ref = {{cascite|changed|??}}
| ATCvet = 
| ATC_prefix = L01
| ATC_suffix = XX49
| PubChem = 6918638
| DrugBank = 
| ChemSpiderID = 5293831
| ChemSpiderID_Ref  = {{chemspidercite|correct|chemspider}}
| UNII = F4H96P17NZ
| UNII_Ref = {{fdacite|correct|FDA}}
| ChEMBL = 408513
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEBI = 61076
| ChEBI_Ref = {{ebicite|correct|EBI}}
| synonyms = PXD101

<!-- Chemical data -->
| C=15|H=14|N=2|O=4|S=1
| molecular_weight  = 318.348 g/mol
| smiles = O=S(=O)(Nc1ccccc1)c2cc(\C=C\C(=O)NO)ccc2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NCNRHFGMJRPRSK-MDZDMXLPSA-N
}}

'''Belinostat''' (trade name '''Beleodaq''', previously known as '''PXD101''') is a [[histone deacetylase inhibitor]] drug developed by [[TopoTarget]] for the treatment of hematological malignancies and solid tumors.<ref>{{Cite journal |author1=Plumb JA |author2=Finn PW |author3=Williams RJ  |display-authors=etal | title = Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101 | journal = Molecular Cancer Therapeutics | year = 2003 | volume = 2 | issue = 8 | pages = 721–728 | pmid = 12939461}}</ref>

It was approved in July 2014 by the [[US FDA]] to treat [[peripheral T-cell lymphoma]].<ref name=FDA-2014/>

In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with [[carboplatin]] and [[paclitaxel]] for relapsed [[ovarian cancer]].<ref>{{cite news |url=http://www.biospace.com/news_story.aspx?NewsEntityId=75000 |title=CuraGen Corporation (CRGN) and TopoTarget A/S Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference |date=October 2007}}</ref> Final results in late 2009 of a phase II trial for [[T-cell lymphoma]] were encouraging.<ref>{{citation |url=http://ash.confex.com/ash/2009/webprogram/Paper20945.html |title= Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma |date=December 2009}}</ref>
Belinostat has been granted [[orphan drug]] and [[FDA Fast Track Development Program|fast track]] designation by the FDA,<ref>{{cite news |url=http://www.fiercebiotech.com/story/spectrum-adds-cancer-pipeline-350m-deal/2010-02-02#ixzz0fBunZz8B |title=Spectrum adds to cancer pipeline with $350M deal. |date=February 2010}}</ref> and was approved in the US for the use against [[peripheral T-cell lymphoma]] on 3 July 2014.<ref name=FDA-2014>{{cite news|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.htm|publisher=FDA|title=FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma
|date=3 July 2014}}</ref> It is not approved in Europe {{as of|2014|8|lc=on}}.<ref name="Spreitzer">{{cite journal
 | author = H. Spreitzer
 | date = 4 August 2014
 | title = Neue Wirkstoffe – Belinostat
 | journal = Österreichische Apothekerzeitung
 | issue = 16/2014
 | pages = 27
 | language = German
 }}</ref>

The approved [[pharmaceutical formulation]] is given [[intravenous]]ly.<ref name=DIHO_2016_14>{{cite book |last1=Lexicomp  |first1= (corporate author) |editor-last=Bragalone  |editor-first=DL  |edition=14th|title=Drug Information Handbook for Oncology|publisher=Wolters Kluwer  |date=2016  |isbn=9781591953517 }}</ref>{{rp|180}}  Belinostat is primarily metabolized by [[UGT1A1]]; the initial dose should be reduced if the recipient is known to be [[homozygous]] for the UGT1A1*28 [[allele]].<ref name=DIHO_2016_14/>{{rp|179 and 181}}

==References==
{{Reflist|2}}


{{Intracellular chemotherapeutic agents}}
{{HDAC inhibitors}}

[[Category:Acrylamides]]
[[Category:Histone deacetylase inhibitors]]
[[Category:Sulfonamides]]
[[Category:Hydroxamic acids]]


{{antineoplastic-drug-stub}}